Adial Pharmaceuticals, Inc. announced it has been awarded an important patent which expands the estate covering the combination of the Company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and drug dependencies, such as opioid use disorder (OUD), with the Company's lead investigational new drug product AD04.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | -1.39% | -10.69% | -23.66% |
04-22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
04-12 | Top Premarket Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.66% | 5.76M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- ADIL Stock
- News Adial Pharmaceuticals, Inc.
- Adial Pharmaceuticals Receives New Patent Notice of Allowance from the United States Patent and Trademark Office